Question 1

Which countries lead Drug-Induced Adverse Reactions research?

Accepted Answer

By volume, the United States and China publish the most (1.2k and 419 works in 2022-now).

Question 2

Which institutions lead Drug-Induced Adverse Reactions research?

Accepted Answer

By volume in 2022-now, Harvard University publishes the most Drug-Induced Adverse Reactions research, followed by Prince Sattam Bin Abdulaziz University and All India Institute of Medical Sciences.

Question 3

Who are the leading researchers in Drug-Induced Adverse Reactions?

Accepted Answer

The most-cited researchers publishing on Drug-Induced Adverse Reactions include David Moher, Mark J. Daly and Giuseppe Remuzzi.

Question 4

Where is Drug-Induced Adverse Reactions research done?

Accepted Answer

The largest centres of Drug-Induced Adverse Reactions research in 2022-now are Paris (France), Tokyo (Japan), Madrid (Spain) and Beijing (China). Among places with at least 20 works in it, it is an unusually large share of all research in Al Kharj and Nashville.

Question 5

Where is the best place to study Drug-Induced Adverse Reactions?

Accepted Answer

Among universities, judged by research, Vanderbilt University, Harvard University and University of Hong Kong score highest, combining citation excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.

Question 6

Is Drug-Induced Adverse Reactions research growing?

Accepted Answer

Output in 2022-2025 was 10% higher than in 2018-2021, peaking in 2021. The fastest-growing topics are Drug-Induced Adverse Reactions.

Question 7

What are the most cited papers in Drug-Induced Adverse Reactions?

Accepted Answer

The most cited paper in Drug-Induced Adverse Reactions is "Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients" (Munir Pirmohamed, Sally James, Shaun Meakin et al., 2004), with 3,262 citations. Next come "Sarcoidosis" (1,973) and "HLA-B*5701 Screening for Hypersensitivity to Abacavir" (1,847).